Live Analyst Rating Changes 24374 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrew Tsai
JEF

Andrew Tsai

Jefferies
Wall Street Analyst
★★★★☆
#889
on 13Foresight · ranked by our own returns
65%
Success Rate
+11.9%
Average Return
28 of 43 calls profitable · +2.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 65% of Andrew Tsai's ratings turned a profit when each position was held for 1 year — averaging +11.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

55 Buy 14 Hold 0 Sell
Andrew's Stock Coverage 27 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BBIO
BridgeBio Pharma
 Aug 11, 2026 BUY Strong Buy
+12.8% avg upside
34 analysts
$110.00
29.93% Upside
 -3.1% ·
AXSM
Axsome Therapeutics
 Aug 11, 2026 BUY Strong Buy
+10.1% avg upside
29 analysts
$380.00
76.84% Upside
 -0.5% ·
DFTX
Definium Therapeutics
 Aug 07, 2026 BUY Strong Buy
+15.8% avg upside
21 analysts
$65.00
51.31% Upside
 -4.9% ·
BIIB
Biogen
 Jul 30, 2026 BUY Strong Buy
+21.4% avg upside
52 analysts
$255.00
22.97% Upside
 +0.4% ·
ATAI
Atai Beckley N.V.
 Jul 17, 2026 HOLD Buy
+33.9% avg upside
17 analysts
$7.50
3.93% Upside
 +0.4% ·
PRAX
Praxis Precision Medicines
 Jun 30, 2026 BUY Strong Buy
+42.1% avg upside
24 analysts
$550.00
45.92% Upside
 +10.1% ·
HELP
Helus Pharma
 Jun 25, 2026 BUY Strong Buy
+236.4% avg upside
13 analysts
$22.00
99.26% Upside
 +92.9% ·
MRNA
Moderna
 Jun 16, 2026 HOLD Hold
+11.9% avg upside
38 analysts
$45.00
29.69% Downside
 +14.9% ·
CMPS
COMPASS Pathways
 May 14, 2026 BUY Strong Buy
+57.6% avg upside
20 analysts
$18.00
28.87% Upside
 +25.1% ·
ANRO
Alto Neuroscience, Inc.
 May 14, 2026 BUY Strong Buy
+4.2% avg upside
13 analysts
$35.00
21.30% Upside
 +36.9% ·
DRUG
Bright Minds Biosciences
 Apr 12, 2026 BUY Strong Buy
+68.3% avg upside
10 analysts
$145.00
81.07% Upside
 -8.4% ·
XENE
Xenon
 Mar 09, 2026 BUY Strong Buy
-4.0% avg upside
28 analysts
$100.00
54.43% Upside
 +2.3% ·
SRPT
Sarepta Therapeutics
 Jan 12, 2026 BUY Buy
+225.4% avg upside
49 analysts
$30.00
62.89% Upside
 -20.6% ·
VNDA
Vanda
 Dec 31, 2025 HOLD Strong Buy
+289.8% avg upside
13 analysts
$7.50
45.28% Upside
 -43.0% ·
VTGN
VistaGen Therapeutics
 Dec 17, 2025 HOLD Hold
+901.4% avg upside
8 analysts
$0.90
247.43% Upside
 -67.4% ·
NERV
Minerva Neurosciences
 Dec 01, 2025 HOLD Buy
+81.5% avg upside
8 analysts
$5.00
20.55% Upside
 +3.2% ·
STOK
Stoke Therapeutics
 Nov 24, 2025 BUY Strong Buy
+21.0% avg upside
18 analysts
$30.00
9.00% Downside
 +7.3% ·
MPLT
MapLight Therapeutics, Inc.
 Nov 21, 2025 BUY Strong Buy
+157.5% avg upside
13 analysts
$32.00
172.71% Upside
 -17.2% ·
ANNX
Annexon Biosciences
 Nov 11, 2025 BUY Strong Buy
+168.0% avg upside
14 analysts
$10.00
90.50% Upside
 +77.1% ·
RCKT
Rocket Pharmaceuticals
 Aug 08, 2025 HOLD Buy
+384.4% avg upside
29 analysts
$3.00
12.46% Downside
 +26.2% ·
LXRX
Lexicon Pharmaceuticals
 Aug 06, 2025 HOLD Buy
+67.7% avg upside
9 analysts
$0.85
64.03% Downside
 +105.2% ·
SVRA
Savara
 Mar 26, 2025 BUY Strong Buy
+52.9% avg upside
17 analysts
$8.50
51.55% Upside
 +94.4% ·
SUPN
Supernus Pharmaceuticals
 Mar 12, 2025 BUY Strong Buy
+18.7% avg upside
9 analysts
$40.00
14.21% Downside
 +60.8% ·
RAPP
Rapport Therapeutics, Inc.
 Dec 07, 2024 BUY Strong Buy
+20.3% avg upside
14 analysts
$35.00
26.41% Downside
 +43.7% ·
LONA
LeonaBio
 Sep 18, 2024 HOLD Buy
+42.7% avg upside
9 analysts
$0.50
93.37% Downside
 -17.3% ·
RLMD
Relmada Therapeutics
 Sep 16, 2024 BUY Buy
+193.5% avg upside
15 analysts
$13.00
181.30% Upside
 -47.2% ·
DYN
Dyne Therapeutics
 Jun 24, 2024 BUY Strong Buy
+51.5% avg upside
31 analysts
$42.00
58.86% Upside
 -70.2% ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrew Tsai — Frequently Asked Questions
How accurate are Andrew Tsai's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Andrew's ratings were profitable over a one-year hold, with an average return of +11.9% per rating, or +2.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andrew ranked on 13Foresight?
Andrew Tsai is currently ranked #889 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrew cover?
Andrew most recently has ratings on BBIO, AXSM, DFTX, BIIB, ATAI, PRAX, HELP, MRNA, CMPS, ANRO, DRUG, XENE and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.